☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
OA study
Pfizer and Eli Lilly Report Results of Tanezumab in P-III OA study (A4091057) for Moderate-To-Severe Osteoarthritis (OA) Pain
January 30, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.